Glyciphage-PG2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated as a sustained-release tablet to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering complementary mechanisms to achieve optimal glycemic control. Glyciphage-PG2 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy with these agents. The sustained-release formulation ensures a gradual release of active ingredients, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. This medication should be used under medical supervision with appropriate monitoring of blood glucose, renal and hepatic function, and cardiovascular status to mitigate potential adverse effects such as hypoglycemia, lactic acidosis, fluid retention, or weight gain.

Dosage & How to Use